Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway

Ning Cui,1 Feng Ding2 1Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, People’s Republic of China; 2Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of ChinaCorrespondence: Feng Ding, Email dingfengkt@163.comBackground: Tumor...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Cui N, Ding F
বিন্যাস: প্রবন্ধ
ভাষা:English
প্রকাশিত: Dove Medical Press 2024-07-01
মালা:Drug Design, Development and Therapy
বিষয়গুলি:
অনলাইন ব্যবহার করুন:https://www.dovepress.com/co-expression-network-analysis-and-molecular-docking-demonstrate-that--peer-reviewed-fulltext-article-DDDT
_version_ 1827181504290095104
author Cui N
Ding F
author_facet Cui N
Ding F
author_sort Cui N
collection DOAJ
description Ning Cui,1 Feng Ding2 1Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, People’s Republic of China; 2Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of ChinaCorrespondence: Feng Ding, Email dingfengkt@163.comBackground: Tumor-Node-Metastasis (TNM) stage of gastric cancer (GC) is one of the main factors affecting clinical outcome. The aim of this study was to explore the targets related to TNM stage of GC, and screening natural bioactive drug.Methods: RNA sequencing data of the TCGA-STAD cohort were downloaded from UCSC database. Genes associated with TNM staging were identified by weighted gene co-expression network analysis (WGCNA). Univariate Cox regression, least absolute shrinkage and selection operator (LASSO), extreme gradient boosting (Xgboost), random forest (RF) and cytohubba plug-in of cytoscope were applied to screen hub genes. Natural bioactive ingredients were available from the HERB database. Molecular docking was used to evaluate the binding activity of active ingredients to the hub protein. CCK-8, flow cytometry, transwell and Western blot assays were used to analyze the effects of diosgenin on GC cells.Results: 898 TNM-related genes were screened out through WGCNA. Three genes associated with GC progression/prognosis were identified, including nuclear receptor subfamily 3 group C member 2 (NR3C2), solute carrier family 1 member 5 (SLC1A5) and FAT atypical cadherin 1 (FAT1) based on the machine learning algorithms and hub co-expression network analysis. Diosgenin had good binding activity with SLC1A5. SLC1A5 was highly expressed in GC and was closely associated with tumor stage, overall survival and immune infiltration of GC patients. Diosgenin could inhibit cell viability and invasive ability, promote apoptosis and induce cell cycle arrest in G0/G1 phase. In addition, diosgenin promoted cleaved caspase 3 expression and inhibited Ki67, cyclin D1, p-S6K1, and SLC1A5 expression levels, while the mTORC1 activator (MHY1485) reversed this phenomenon.Conclusion: For the first time, this work reports diosgenin may inhibit the activation of mTORC1 signaling through targeting SLC1A5, thereby inhibiting the malignant behaviors of GC cells.Keywords: gastric cancer, weighted gene co-expression network analysis, diosgenin, molecular docking, diosgenin
first_indexed 2025-03-21T05:47:52Z
format Article
id doaj.art-02477d1f01124251b51c852a38f0c93f
institution Directory Open Access Journal
issn 1177-8881
language English
last_indexed 2025-03-21T05:47:52Z
publishDate 2024-07-01
publisher Dove Medical Press
record_format Article
series Drug Design, Development and Therapy
spelling doaj.art-02477d1f01124251b51c852a38f0c93f2024-07-23T18:28:48ZengDove Medical PressDrug Design, Development and Therapy1177-88812024-07-01Volume 183157317394464Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 PathwayCui NDing FNing Cui,1 Feng Ding2 1Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, People’s Republic of China; 2Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of ChinaCorrespondence: Feng Ding, Email dingfengkt@163.comBackground: Tumor-Node-Metastasis (TNM) stage of gastric cancer (GC) is one of the main factors affecting clinical outcome. The aim of this study was to explore the targets related to TNM stage of GC, and screening natural bioactive drug.Methods: RNA sequencing data of the TCGA-STAD cohort were downloaded from UCSC database. Genes associated with TNM staging were identified by weighted gene co-expression network analysis (WGCNA). Univariate Cox regression, least absolute shrinkage and selection operator (LASSO), extreme gradient boosting (Xgboost), random forest (RF) and cytohubba plug-in of cytoscope were applied to screen hub genes. Natural bioactive ingredients were available from the HERB database. Molecular docking was used to evaluate the binding activity of active ingredients to the hub protein. CCK-8, flow cytometry, transwell and Western blot assays were used to analyze the effects of diosgenin on GC cells.Results: 898 TNM-related genes were screened out through WGCNA. Three genes associated with GC progression/prognosis were identified, including nuclear receptor subfamily 3 group C member 2 (NR3C2), solute carrier family 1 member 5 (SLC1A5) and FAT atypical cadherin 1 (FAT1) based on the machine learning algorithms and hub co-expression network analysis. Diosgenin had good binding activity with SLC1A5. SLC1A5 was highly expressed in GC and was closely associated with tumor stage, overall survival and immune infiltration of GC patients. Diosgenin could inhibit cell viability and invasive ability, promote apoptosis and induce cell cycle arrest in G0/G1 phase. In addition, diosgenin promoted cleaved caspase 3 expression and inhibited Ki67, cyclin D1, p-S6K1, and SLC1A5 expression levels, while the mTORC1 activator (MHY1485) reversed this phenomenon.Conclusion: For the first time, this work reports diosgenin may inhibit the activation of mTORC1 signaling through targeting SLC1A5, thereby inhibiting the malignant behaviors of GC cells.Keywords: gastric cancer, weighted gene co-expression network analysis, diosgenin, molecular docking, diosgeninhttps://www.dovepress.com/co-expression-network-analysis-and-molecular-docking-demonstrate-that--peer-reviewed-fulltext-article-DDDTgastric cancerweighted gene co-expression network analysisdiosgeninmolecular dockingdiosgenin.
spellingShingle Cui N
Ding F
Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway
Drug Design, Development and Therapy
gastric cancer
weighted gene co-expression network analysis
diosgenin
molecular docking
diosgenin.
title Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway
title_full Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway
title_fullStr Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway
title_full_unstemmed Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway
title_short Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway
title_sort co expression network analysis and molecular docking demonstrate that diosgenin inhibits gastric cancer progression via slc1a5 mtorc1 pathway
topic gastric cancer
weighted gene co-expression network analysis
diosgenin
molecular docking
diosgenin.
url https://www.dovepress.com/co-expression-network-analysis-and-molecular-docking-demonstrate-that--peer-reviewed-fulltext-article-DDDT
work_keys_str_mv AT cuin coexpressionnetworkanalysisandmoleculardockingdemonstratethatdiosgenininhibitsgastriccancerprogressionviaslc1a5mtorc1pathway
AT dingf coexpressionnetworkanalysisandmoleculardockingdemonstratethatdiosgenininhibitsgastriccancerprogressionviaslc1a5mtorc1pathway